<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076685</url>
  </required_header>
  <id_info>
    <org_study_id>200805015M</org_study_id>
    <nct_id>NCT02076685</nct_id>
  </id_info>
  <brief_title>NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis</brief_title>
  <official_title>The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To improve the treatment outcome in patients with tuberculosis and integrate the
      pharmacogenetics into clinical practice, the information of NAT2 genotyping was used in
      re-challenge protocol for isoniazid (INH) titration in patients with anti-tuberculosis
      medication-induced hepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>successful re-use of isoniazid for TB treatment</measure>
    <time_frame>6 months</time_frame>
    <description>In this study, we would like to test the hypothesis of NAT2 genotyping helping in isoniazid rechallenge after patients experienced adverse effects of anti-TB treatment. Therefore, to observe the patients can re-use isoniazid successfully is an important outcome measure in this study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatotoxicity</condition>
  <arm_group>
    <arm_group_label>isoniazid rechalleng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoniazid</intervention_name>
    <description>dose adjustment according to the pharmacogenomic results</description>
    <arm_group_label>isoniazid rechalleng</arm_group_label>
    <other_name>Duracin, Rifina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;= 18 years.

          2. Take INH for at least a week.

          3. abnormal liver function (ALT (alanine, transaminase) increased by more than three
             times the upper limit of normal, or ALT higher than twice the upper limit of normal
             and total bilirubin higher than 2.0 mg / dL

        Exclusion Criteria:

        1.Taking INH before liver function abnormalities. 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Li Jiuan, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationa Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Jiuan Shen, Ph.D.</last_name>
    <email>ljshen@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Jiuan Shen, Ph.D.</last_name>
      <email>ljshen@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Li-Jiuan Shen, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacogenetics</keyword>
  <keyword>anti-tuberculosis drug</keyword>
  <keyword>genetic polymorphism</keyword>
  <keyword>isoniazid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

